Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V. Long, Dirk Schadendorf, Uwe Trefzer et al.|The Lancet Oncology|2012Cited by 906